The French ‘private equity’ will integrate the company into the French giant EA Pharma

More movements in Spanish corporate operations. The French laboratory EA Pharma, controlled by the venture capital firm, also French, Motion, has closed this Thursday the purchase of a majority stake in Dransanvi, based in León and one of the main Spanish companies dedicated to development, manufacturing, marketing and distribution of food supplements and natural cosmetics. The buyer’s adviser was GBS Finance and the seller’s was AnquorCF.

In Spain there are about 800 companies dedicated to importing, producing or marketing this type of product. The country is a benchmark at the international level and with an important projection in the Latin American market. “Its marketing channels are 30,000 points of sale distributed among pharmacies, parapharmacies, bio stores, herbalists, mass consumption and online, within a market with a turnover that exceeds 1,000 million euros each year.

Jonathan Bienfait, CEO of EA Pharma states in a note that “this strategic alliance will allow Drasanvi to benefit from EA Pharma’s complementary product portfolio, as well as its human and financial resources. Reciprocally, Drasanvi will increase the geographical presence of EA Pharma thanks to its extensive network in Spain, improving our product portfolio with its wide range of food supplements and its own references in cosmetics and nutrition.”

For his part, Oscar López, CEO of Drasanvi states that “it is a pleasure for us to join forces with one of the main groups in the sector such as EA Pharma within a market in consolidation, and where many of our main competitors are larger groups and with more resources. This union guarantees not only a bright future for a family-based company like Drasanvi, but also the continuity of the current project thanks to the talent and know-how of an international benchmark in the sector like EA Pharma”.

For EA Pharma, majority owned by the Private Equity fund Motion Equity Partners, this is its first corporate operation in Spain, after having previously acquired DUAB in France from Laboratoire Nutrivercell in 2017, the Punch Power brand from Oligostim in 2019 and Laboratoire Labcatal in 2020.

Who’s who

Founded in León in 1993, Drasanvi is a leading Spanish company specializing in the development, manufacture, marketing and distribution of food supplements and natural cosmetics. It has a portfolio with more than 30 brands and 350 SKUs that covers four key market sectors: Food Supplements, Organic Cosmetics, Sports Nutrition and Superfoods. Its range of products is indicated in countless cares and treatments for bones, joints, nutrition, maintenance of skin and hair in good condition, cardiovascular health, digestive and hepatic systems, rest, circulation, energy and vitality, beauty or sports performance. .

Drasanvi employs more than 100 people, and has its own commercial team specialized in the herbal, pharmaceutical and parapharmaceutical channel that covers the entire Spanish territory and also internationally, with its own subsidiary in Costa Rica, commercial delegations in Chile, Mexico, Peru and Portugal, in addition to successful commercial relations in countries such as France, the United Kingdom, Russia and China, where it has recently signed an agreement to grow in the country with the pharmaceutical multinational Sinopharm.

EA Pharma is a French pharmaceutical laboratory specializing in oligotherapy, sports nutrition and micronutrition, the result of the merger of three companies: Équilibre Attitude, Le Laboratoire des Granions and Les Laboratoires Merle.

Since 2017, EA Pharma has been majority owned by Motion Equity Partners (MEP), a European venture capital fund focused on the middle market with €500 million under management and more than 50 successful acquisitions over the last decade, most of them international. Motion aims to help EA Pharma to become a benchmark within the sector at an international level, through strategic alliances and the acquisition of other companies in the sector.

Font: https://cincodias.elpais.com/cincodias/2021/09/30/companias/1633003635_564673.html